Literature DB >> 3025016

Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing.

P A Andreasen, A Riccio, K G Welinder, R Douglas, R Sartorio, L S Nielsen, C Oppenheimer, F Blasi, K Danø.   

Abstract

Both the urokinase-type and tissue-type plasminogen activator can convert their approximately 54 kDa type-1 inhibitor (PAI-1) to an inactive form with a lower apparent molecular mass. We have determined the amino-terminal amino acid sequences of human native and converted PAI-1, and isolated PAI-1 cDNA and determined the nucleotide sequence in regions corresponding to the amino-terminus and the cleavage site. The data show that the conversion of the inhibitor consists of cleavage of an Arg-Met bond 33 residues from the carboxy-terminus, thus localizing the reactive center of the inhibitor to that position. In addition, a heterogeneity was found at the amino-terminus, with a Ser-Ala-Val-His-His form and a two-residue shorter form (Val-His-His-) occurring in approximately equal quantities.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3025016     DOI: 10.1016/0014-5793(86)81113-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  37 in total

1.  Evidence for the involvement of protein kinase activity in transforming growth factor-beta signal transduction.

Authors:  M Ohtsuki; J Massagué
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

2.  Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.

Authors:  P Kristensen; C Pyke; L R Lund; P A Andreasen; K Danø
Journal:  Histochemistry       Date:  1990

3.  The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator.

Authors:  T L Lindahl; P I Ohlsson; B Wiman
Journal:  Biochem J       Date:  1990-01-01       Impact factor: 3.857

4.  Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.

Authors:  P H Quax; N Pedersen; M T Masucci; E J Weening-Verhoeff; K Danø; J H Verheijen; F Blasi
Journal:  Cell Regul       Date:  1991-10

5.  Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.

Authors:  D E Vaughan; P J Declerck; M De Mol; D Collen
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

6.  The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1.

Authors:  G C Prendergast; L E Diamond; D Dahl; M D Cole
Journal:  Mol Cell Biol       Date:  1990-03       Impact factor: 4.272

7.  Plasminogen activator inhibitor (type-1) in rat adrenal medulla.

Authors:  J Eriksen; P Kristensen; C Pyke; K Danø
Journal:  Histochemistry       Date:  1989

8.  Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture.

Authors:  Edson Mantovani Barbosa; Sueli Nonogaki; Maria Lucia Hirata Katayama; Maria Aparecida Azevedo Koike Folgueira; Venâncio Ferreira Avancini Alves; Maria Mitzi Brentani
Journal:  Virchows Arch       Date:  2003-12-02       Impact factor: 4.064

9.  Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1.

Authors:  Anja P Einholm; Katrine E Pedersen; Troels Wind; Paulina Kulig; Michael T Overgaard; Jan K Jensen; Julie S Bødker; Anni Christensen; Peter Charlton; Peter A Andreasen
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

10.  Opposite and independent actions of cyclic AMP and transforming growth factor beta in the regulation of type 1 plasminogen activator inhibitor expression.

Authors:  F W Thalacker; M Nilsen-Hamilton
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.